AVITA Medical Just Tripled Its TAM In The Burn Market
AVITA Medical's Q3 report showed strong sequential sales growth and a lower burn rate. My confidence in it reaching breakeven by Q3 2025 has increased. The transition to RECELL GO has been highly successful, with 75% of the US sales base switching from the manual version. This is driving increased utilization. The total addressable market for AVITA's new ecosystem of products has expanded significantly, with the burning market TAM increasing from $450 million to $1.5 billion.
AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Ross Osborne - Cantor Fitzgerald Eric Anderson - TD Cowen John Hester - Bell Potter Chris Kallos - MST Access Operator Good day and thank you for standing by. Welcome to the AVITA Medical, Inc. Third Quarter 2024 Earnings Conference Call.
AVITA Medical Headed For Its Most Important Report, I'm Extremely Bullish
AVITA Medical's RECELL GO offers superior wound healing with less donor skin required, reducing scarring and infection risk. It has no direct competition. RECELL GO streamlines the skin grafting process, saving time and money. New products like PermeaDerm and Cohealyx offer additional growth opportunities. Despite the Q1 sales hiccup & high operating losses, AVITA's underlying technology still has promise. The stock should rally if the Q3 sales target is met & operating margins improve.
AVITA Medical: New Products, Same Old Cash Burn (Rating Downgrade)
RECELL GO's launch increased SG&A expenses, contributing to AVITA Medical, Inc.'s higher net losses in Q2 2024. Despite lowering its 2024 revenue guidance, AVITA Medical still anticipates significant year-over-year growth of 37-41%. AVITA Medical's cash runway is approximately nine months, with $54.1 million in cash and securities available as of June 30, 2024.
AVITA Medical, Inc. (RCEL) Q2 2024 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Joshua Jennings - TD Cowen Aaron Wukmir - Lake Street Capital Market Ross Osborne - Cantor Fitzgerald Lyanne Harrison - Bank of America Operator Good day and thank you for standing by. Welcome to the AVITA Medical Second Quarter Conference Call.
